Oral hedgehog-pathway inhibitors for basal-cell carcinoma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed, 7 syntheses or guidelines pooled it.

1. Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults.The Cochrane database of systematic reviews · 2018
   Pooled it
2. High-frequency ultrasound for diagnosing skin cancer in adults.The Cochrane database of systematic reviews · 2018
   Pooled it
3. Teledermatology for diagnosing skin cancer in adults.The Cochrane database of systematic reviews · 2018
   Pooled it
4. Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults.The Cochrane database of systematic reviews · 2018
   Pooled it
5. Optical coherence tomography for diagnosing skin cancer in adults.The Cochrane database of systematic reviews · 2018
   Pooled it
6. Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults.The Cochrane database of systematic reviews · 2018
   Pooled it
7. Visual inspection and dermoscopy, alone or in combination, for diagnosing keratinocyte skin cancers in adults.The Cochrane database of systematic reviews · 2018
   Pooled it
8. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.BMC cancer · 2017
   Trial
9. A case of basal cell carcinoma of skin with bone metastasis: a case report.Journal of medical case reports · 2024
   Article
10. Advanced and Metastatic Non-Melanoma Skin Cancer: Epidemiology, Risk Factors, Clinical Features, and Treatment Options.Biomedicines · 2024
    Review
11. Cutaneous Basal Cell Carcinoma with Bone Metastases: An Orthopaedic Case Report.Case reports in orthopedics · 2019
    Article
12. Vismodegib for Locally Advanced Periocular and Orbital Basal Cell Carcinoma: A Review of 15 Consecutive Cases.Plastic and reconstructive surgery. Global open · 2017
    Article
13. Bmi-1 serves as a potential novel marker for progression in human cutaneous basal cell carcinoma.International journal of clinical and experimental pathology · 2017
    Article
14. Non-melanoma skin cancer.Clinical medicine (London, England) · 2016
    Article
15. Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective.British journal of cancer · 2014
    Article
16. Can we safely target the WNT pathway?Nature reviews. Drug discovery · 2014
    Review
17. Imiquimod directly inhibits Hedgehog signalling by stimulating adenosine receptor/protein kinase A-mediated GLI phosphorylation.Oncogene · 2013
    Article
18. Vismodegib as eye-sparing adjuvant treatment for orbital basal cell carcinoma.JAMA ophthalmology · 2013
    Article
19. Morphogen pathways in systemic sclerosis.Current rheumatology reports · 2013
    Review

Corrections and comments

• Commented on by
  Vismodegib in advanced basal-cell carcinoma.2012
• Comment on
  Efficacy and safety of vismodegib in advanced basal-cell carcinoma.2012
• Comment on
  Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.2012

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as